2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08C.04 Personalized ctDNAand CTC Dynamic Monitoring to Predict Response of Tislelizumab-Based Therapy in Unresectable LA-NSCLC

EP.08C.04 Personalized ctDNAand CTC Dynamic Monitoring to Predict Response of Tislelizumab-Based Therapy in Unresectable LA-NSCLC

Back to course

Pdf Summary

This document details a study on the dynamic monitoring of personalized circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) to predict the response to Tislelizumab-based therapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Tislelizumab, a PD-1 monoclonal antibody, is explored as both an induction and consolidation treatment combined with chemotherapy, followed by concurrent chemoradiotherapy (cCRT).<br /><br />The study involved 30 patients receiving this treatment regimen, emphasizing monitoring through blood samples for ctDNA and CTC as potential predictive biomarkers for therapy response. The primary endpoint was the rate of progression-free survival at one year (1y-PFS), with secondary endpoints assessing overall survival rate, objective response rate (ORR), disease control rate (DCR), and treatment safety.<br /><br />Key findings include:<br />- Tislelizumab combined with chemotherapy as induction therapy showed an ORR of 50% and a DCR of 100% after the induction phase.<br />- There was a significant decline in ctDNA levels post-induction therapy, especially among those achieving partial response (PR).<br />- Higher baseline ctDNA levels were noted in the stable disease (SD) group compared to the PR group, indicating that ctDNA levels can potentially predict best response.<br />- The treatment was well tolerated, with 10% of patients experiencing grade 3 treatment-related adverse events, and no grade 4 or 5 events were reported.<br />- ctDNA clearance post-induction was associated with a higher likelihood of achieving PR.<br />- CTC metrics, including PD-L1 positive CTCs, showed correlations with treatment efficacy but require further exploration.<br /><br />Overall, the study suggests that ctDNA and CTC measurements can be valuable in predicting and monitoring responses in Tislelizumab-based therapies for LA-NSCLC, though further research is needed to confirm these findings.

Asset Subtitle

Jing Wang

Meta Tag

Speaker Jing Wang

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

personalized ctDNA

circulating tumor cells

Tislelizumab therapy

non-small cell lung cancer

predictive biomarkers

progression-free survival

objective response rate

disease control rate

treatment safety

PD-1 monoclonal antibody